Company Information

BALAXI PHARMACEUTICALS LTD.

NSE : BALAXIBSE : ISIN CODE : INE618N01014Industry : TradingHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( )0 0
NSE574.75-5.05 (-0.87 %)
PREV CLOSE( ) 579.80
OPEN PRICE ( ) 582.90
BID PRICE (QTY) 574.75 (30)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4082
TODAY'S LOW / HIGH( ) 565.55 582.90
52 WK LOW / HIGH ( )399.95 686.3
Managing DirectorAshish Maheshwari
Company SecretaryUdayan Abhilash Shukla
Non Executive DirectorMinoshi Maheshwari
Non Executive Independent DirectorKunal M Bhakta
Gandhi Gamji
Mangina Srinivas Rao
Purnima Singh
Incorporation Year : 28-09 1942

Registered Office :

Address : Plot No. 409, H. No. 8-2-293,Maps Towers, 3rd Floor, Phase I I I,Road No. 81, Jubilee Hills Hyderabad,
Telangana-500096 .

Phone : 040 23555300

Email :  info@balaxi.in 

Industry : Trading

Listing : NSE,Chennai

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.